We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+4.64%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$106B
AUM Growth
+$2.27B
Cap. Flow
-$488M
Cap. Flow %
-0.46%
Top 10 Hldgs %
30.07%
Holding
4,478
New
179
Increased
2,056
Reduced
1,848
Closed
61

Top Buys

Rank Stock Value
1
XOM icon
ExxonMobil
XOM
+$101M
2
GEV icon
GE Vernova
GEV
+$75.4M
3
CRH icon
CRH
CRH
+$48.5M
4
CRWD icon
CrowdStrike
CRWD
+$45.8M
5
DELL icon
Dell
DELL
+$35.8M

Sector Composition

Rank Sector Weight
1 Technology 30.98%
2 Financials 12.55%
3 Healthcare 11.48%
4 Consumer Discretionary 10.52%
5 Industrials 8.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ZVRA icon
2876
Zevra Therapeutics
ZVRA
$686M
$279K ﹤0.01%
56,874
+8,619
+18% +$40.8K
KRRO icon
2877
Korro Bio
KRRO
$195M
$279K ﹤0.01%
+8,227
New +$455K
ONC
2878
BeOne Medicines Ltd
ONC
$39.4B
$278K ﹤0.01%
1,951
-150
-7% -$23.1K
MBCN
2879
DELISTED
Middlefield Banc Corp
MBCN
$278K ﹤0.01%
11,573
-326
-3% -$7.27K
WEYS icon
2880
Weyco Group
WEYS
$440M
$278K ﹤0.01%
9,156
+140
+2% +$4.14K
NATH icon
2881
Nathan's Famous
NATH
$402M
$276K ﹤0.01%
4,074
+110
+3% +$7.44K
PLTK icon
2882
Playtika
PLTK
$1.12B
$276K ﹤0.01%
35,014
-4,814
-12% -$38.2K
VMD icon
2883
Viemed Healthcare
VMD
$371M
$275K ﹤0.01%
42,011
+3,613
+9% +$27.2K
RYAAY icon
2884
Ryanair
RYAAY
$31.3B
$275K ﹤0.01%
5,905
-270
-4% -$14K
TCRX icon
2885
TScan Therapeutics
TCRX
$52M
$274K ﹤0.01%
+46,867
New +$369K
TUR icon
2886
iShares MSCI Turkey ETF
TUR
$213M
$274K ﹤0.01%
6,520
+300
+5% +$12.2K
PCB icon
2887
PCB Bancorp
PCB
$391M
$274K ﹤0.01%
16,804
-99
-0.6% -$1.51K
PKBK icon
2888
Parke Bancorp
PKBK
$405M
$274K ﹤0.01%
15,722
+82
+0.5% +$1.34K
ALCO icon
2889
Alico
ALCO
$283M
$273K ﹤0.01%
10,552
-121
-1% -$3.27K
KRT icon
2890
Karat Packaging
KRT
$940M
$272K ﹤0.01%
9,203
+387
+4% +$10.9K
SGHT icon
2891
Sight Sciences
SGHT
$412M
$272K ﹤0.01%
40,811
+11,671
+40% +$69K
ADCT icon
2892
ADC Therapeutics
ADCT
$144M
$272K ﹤0.01%
+85,977
New +$342K
YPF icon
2893
YPF Sociedad Anonima American Depositary Shares (Each representing ten (10) Class D shares of Capital Stock)
YPF
$19.3B
$270K ﹤0.01%
13,415
BN icon
2894
Brookfield
BN
$108B
$269K ﹤0.01%
9,699
-2,637
-21% -$73.5K
BARK icon
2895
BARK
BARK
$101M
$268K ﹤0.01%
7,417
+809
+12% +$20.7K
CHRS icon
2896
Coherus Oncology
CHRS
$196M
$268K ﹤0.01%
154,904
+25,241
+19% +$50.8K
WPM icon
2897
Wheaton Precious Metals
WPM
$60.9B
$268K ﹤0.01%
5,105
-245
-5% -$13.1K
PINE
2898
Alpine Income Property Trust
PINE
$352M
$268K ﹤0.01%
17,197
+1,272
+8% +$19.5K
FVCB icon
2899
FVCBankcorp
FVCB
$333M
$267K ﹤0.01%
24,468
+467
+2% +$5.17K
CLMB icon
2900
Climb Global Solutions
CLMB
$519M
$266K ﹤0.01%
16,956
+948
+6% +$14.4K

Similar funds

RhumbLine Advisers's Q2 2024 Portfolio in Review

As of Q2 2024, RhumbLine Advisers held 4,478 positions worth $106B, up 2.2% from $104B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

RhumbLine Advisers's Q2 2024 filing shows 179 new, 2,056 increased, 1,848 reduced and 61 closed positions. Its largest new stake was GE Vernova: 475,685 shares worth $81.6M. The largest sale was iShares Russell 1000 ETF, an estimated $180M.

By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 28% a quarter earlier, followed by Financials and Healthcare.

  • RhumbLine Advisers's largest Q2 2024 buy was GE Vernova: 475,685 shares worth $81.6M.
  • RhumbLine Advisers added most to ExxonMobil in Q2 2024, an estimated $101M increase.
  • RhumbLine Advisers's biggest Q2 2024 reduction was iShares Russell 1000 ETF, cutting an estimated $180M.
  • RhumbLine Advisers fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $121M.
  • RhumbLine Advisers's ten largest holdings make up 30% of its $106B portfolio in Q2 2024.
  • RhumbLine Advisers opened 179 new positions and closed 61 in Q2 2024.
  • RhumbLine Advisers's portfolio value rose 2.2% quarter-over-quarter to $106B.

Based on RhumbLine Advisers's 13F filing for Q2 2024, filed 1 Aug 2024.